RPRX
Royalty Pharma (RPRX)
$79
About Royalty Pharma (RPRX)
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Details
Daily high
$51.17
Daily low
$50.50
Price at open
$50.78
52 Week High
$51.65
52 Week Low
$32.15
Market cap
22.6B
Dividend yield
1.76%
Volume
3.8M
Avg. volume
3.3M
P/E ratio
26.60
Royalty Pharma News
Details
Daily high
$51.17
Daily low
$50.50
Price at open
$50.78
52 Week High
$51.65
52 Week Low
$32.15
Market cap
22.6B
Dividend yield
1.76%
Volume
3.8M
Avg. volume
3.3M
P/E ratio
26.60